Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
4168.TWO
STRONG SELLREMOVEGlycoNex Incorporation · Healthcare · Taiwan · $91M · Avg Vol: $475K/d
GlycoNex is a small-scale biotech with no commercialized high-margin products or CDMO capabilities, failing our quality screens.
COMPANY DESCRIPTION
GlycoNex Incorporation is a clinical-stage biotechnology company specializing in the development of glycan-targeted monoclonal antibodies for cancer immunotherapy. The company’s proprietary carbohydrate-based antigen platform allows it to identify and target novel tumor-associated antigens with high specificity. It operates as an R&D-focused innovator, seeking to license its oncology pipeline candidates to global pharmaceutical partners for late-stage development.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 1.0M | 80,318 | 0.5M | 1.2M | 8.0% |
| EPS | -0.06 | -0.07 | -0.05 | -0.07 | — | — |
| Shares | — | 107.4M | 108.5M | 108.5M | 112.5M | +4.8% |
| Debt | — | 7.1M | 28,437 | 28,437 | 15.0M | 28.3% |
| Equity | — | 45.7M | 40.3M | 33.1M | 31.0M | -12.1% |
| Op CF | — | -5.3M | -5.8M | -7.0M | -5.3M | — |
| Inv CF | — | -12.6M | 8.1M | 5.8M | 3.1M | — |
| Fin CF | — | 16.6M | -0.2M | 379 | 13.5M | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 4168.TWO are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 4168.TWO | GlycoNex Incorporation(you) | $91M | 17 | STRONG SELL |
| 6492.TWO | Senhwa Biosciences, Inc. | $121M | 17 | STRONG SELL |
| 6733.TWO | BioGend Therapeutics Co., Ltd. | $102M | 12 | STRONG SELL |
| 6838.TW | Formosa Pharmaceuticals, Inc. | $116M | 15 | STRONG SELL |
| 6885.TW | BRIM Biotechnology, Inc. | $91M | 9 | STRONG SELL |
| 4178.TW | StemCyte International, Ltd. | $117M | 12 | STRONG SELL |
| 6657.TW | Energenesis Biomedical CO.,LTD. | $101M | 8 | STRONG SELL |
| 6461.TWO | Intech Biopharm Corporation | $84M | 6 | STRONG SELL |
| 6794.TW | UnicoCell Biomed Co., Ltd. | $159M | 18 | STRONG SELL |
| 3205.TWO | Sagittarius Life Science Corp | $111M | 26 | SELL |
Peer medians: ROE 3.6% · P/E 16.2x · Gross margin 42.1%